Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Poliwoda

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
Cancer Biotherapy|January 1, 1993
Limited efficacy of interferon-alpha and vinblastine as second line biochemotherapy regimen in patients with progressive metastatic renal cell carcinomaE Lopez Hanninen, M Fenner, H Kirchner, et al.
World Journal of Urology|January 1, 1995
Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acidJ Atzpodien, H Kirchner, S Duensing, et al.
American Journal of Clinical Oncology|June 1, 1994
Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapyA Schomburg, H Kirchner, E Lopez-Hänninen, et al.
Molecular Biotherapy|December 1, 1992
Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alphaS Duensing, M Hadam, A Körfer, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumoursC Schöber, E Schmoll, H J Schmoll, et al.
British Journal of Cancer|June 1, 1995
Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanomaW H Kruit, S H Goey, F Calabresi, et al.
The Clinical Investigator|July 1, 1994
Cytokine-based biotherapy of gastrointestinal tumorsJ Buer, H Kirchner, A Schomburg, et al.
Cancer Research|December 1, 1991
Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypesE L Hänninen, A Körfer, M Hadam, et al.
Cancer Biotherapy|January 1, 1993
Clinical and preclinical evaluation of recombinant PEG-IL-2 in humanT Menzel, A Schomburg, A Körfer, et al.
Cancer Biotherapy|January 1, 1993
Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II StudyJ Atzpodien, H Kirchner, P de Mulder, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
Cancer Biotherapy|January 1, 1993
Limited efficacy of interferon-alpha and vinblastine as second line biochemotherapy regimen in patients with progressive metastatic renal cell carcinomaE Lopez Hanninen, M Fenner, H Kirchner, et al.
World Journal of Urology|January 1, 1995
Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acidJ Atzpodien, H Kirchner, S Duensing, et al.
American Journal of Clinical Oncology|June 1, 1994
Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapyA Schomburg, H Kirchner, E Lopez-Hänninen, et al.
Molecular Biotherapy|December 1, 1992
Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alphaS Duensing, M Hadam, A Körfer, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumoursC Schöber, E Schmoll, H J Schmoll, et al.
British Journal of Cancer|June 1, 1995
Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanomaW H Kruit, S H Goey, F Calabresi, et al.
The Clinical Investigator|July 1, 1994
Cytokine-based biotherapy of gastrointestinal tumorsJ Buer, H Kirchner, A Schomburg, et al.
Cancer Research|December 1, 1991
Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypesE L Hänninen, A Körfer, M Hadam, et al.
Cancer Biotherapy|January 1, 1993
Clinical and preclinical evaluation of recombinant PEG-IL-2 in humanT Menzel, A Schomburg, A Körfer, et al.
Cancer Biotherapy|January 1, 1993
Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II StudyJ Atzpodien, H Kirchner, P de Mulder, et al.
Pageof 10